BIB_135
HCQ + dabrafenib + trametinib trial in BRAF V600 melanoma post-progression. PMID 35377866 (2022). Phase 2; small numbers; rationale autophagy-driven resistance. [Tasks: 12, 18] Tier: 3 Grade: B Retrieved: 2026-05-07
- Evidence grade
- B
- Tier
- 3
- Cited by tasks
- 12, 18
- Identifiers
- PMID:35377866
↗ Follow the original source for full context
Full extracted findings & patient-implication analysis: bibliography/BIB_135/findings.md (research corpus). This page is a short context summary — not individualised medical advice.